<html xmlns:fo="http://www.w3.org/1999/XSL/Format">

<!-- Mirrored from www.zambiahivguide.org/drugs/antiretrovirals/full_etravirine.html by HTTrack Website Copier/3.x [XR&CO'2007], Thu, 19 Jun 2008 21:24:50 GMT -->
<head>
<META http-equiv="Content-Type" content="text/html; charset=iso-8859-1">
<title>Johns Hopkins POC-IT: Point of Care Information Technology</title>
<meta content="text/html; charset=iso-8859-1" http-equiv="Content-Type">
<link href="../../images/styles.css" type="text/css" rel="stylesheet">
<script type="text/JavaScript" src="../../images/functions.js" language="JavaScript"></script>
</head>
<body>
<table cellspacing="0" cellpadding="0" border="0">
<tr>
<td>Johns Hopkins POC-IT: Point of Care Information Technology</td><td >
<table cellspacing="0" cellpadding="0" border="0">
<tr>
<td >
<table cellspacing="0" cellpadding="0" border="0">
<tr>
<td></td><td>
<table cellspacing="0" cellpadding="0" border="0">
<tr>
<td class="tdVAlignMiddle" align="center" >
                                                            &nbsp;</td>
</tr>
<tr></tr>
</table>
</td>
</tr>
</table>
</td>
</tr>
<tr>
<td  ><span class="mainNav">&nbsp;Print-Friendly Module</span></td>
</tr>
</table>
</td>
</tr>
</table>
<p></p>
<table cellspacing="0" cellpadding="0" border="0" >
<tr>
<td></td><td>
<table >
<tr>
<td><span class="primaryItemTitle"><font size="6">Etravirine</font></span>
<br>
</td><td align="right" valign="top"><a href="javascript:window.print();"></a></td>
</tr>
<tr>
<td colspan="2">
<br>
        Author: <author maxOccurance="1" tag="author" use="required">Paul A. Pham Pharm.D.</author>
<br>
<span class="display_date">04-28-2008</span>
<br>
<div style="background-color:#ccffcc;">
<a name=""></a>
<h2 class="grayLineHeaderBar"></h2>
<ul>
<li>Etravirine not currently available in Zambia</li>
</ul>Zambia Information Author: Paul A. Pham, Pharm. D. <br>
<br>
</div>
<a name="INDICATIONS"></a>
<h2 class="grayLineHeaderBar">INDICATIONS</h2>
<table  cellspacing="0" cellpadding="0" border="0">
<tr>
<td><span class="header12px">FDA</span></td>
</tr>
</table>
<hr>
<ul>
<li>In combination with other ARV agents for the treatment of HIV-1 infection in treatment-experienced pts with PIs, NRTIs, and NNRTI-resistant variants.</li>
</ul>
<table  cellspacing="0" cellpadding="0" border="0">
<tr>
<td><span class="header12px">NON-FDA APPROVED USES</span></td>
</tr>
</table>
<hr>
<ul>
<li>Potential for use in first-line therapy for pts infected with NNRTI-resistant virus (untested) </li>
</ul>
<a name="FORMS"></a>
<h2 class="grayLineHeaderBar">FORMS</h2>
<TABLE  class="blueOutline" cellspacing="0" cellpadding="2" border="0">
<TR class="blueBarBG">
<TD><B>brand name</B></TD><TD><B>preparation</B></TD><TD><B>manufacturer</B></TD><TD><B>route</B></TD><TD><B>form</B></TD><TD><B>dosage^</B></TD><TD><B>cost*</B></TD>
</TR>
        
<TR>
<TD valign="top">Intelence</TD><TD valign="top">Etravirine (ETR)</TD><TD valign="top">Tibotec Pharmaceuticals </TD><TD>Oral</TD><TD>tablet</TD><TD>100 mg </TD><TD>$5.45 per tab </TD>
</TR>
      
</TABLE>
<p>*Costs (rounded to the nearest dollar) are based on usual adult dosing per day, 
                are representative of "Average Wholesale Price" (AWP), and are current within the prior three months.</p>
<p>^Dosage is indicated in mg unless otherwise noted.</p>
<a name="USUAL ADULT DOSING"></a>
<h2 class="grayLineHeaderBar">USUAL ADULT DOSING</h2>Pill burden: 4 tabs/day.<br>
<br>
<ul>
<li>ETR 200 mg bid with food</li>
<li>With <A class="headLines" target="_new" href="maraviroc7e32.html?contentInstanceId=443126">MVC</A>: <A class="headLines" target="_new" href="maraviroc7e32.html?contentInstanceId=443126">MVC</A> 600 mg bid plus ETR 200 mg bid with food.</li>
<li>With <A class="headLines" target="_new" href="maraviroc7e32.html?contentInstanceId=443126">MVC</A> + boosted PI: <A class="headLines" target="_new" href="maraviroc7e32.html?contentInstanceId=443126">MVC</A> 150 mg bid + ETR 200 mg bid with food.</li>
<li>With DRV/r: DRV/r 600/100mg bid + ETR 200 mg bid with food.</li>
<li>With RAL: RAL 400 mg bid + ETR 200 mg bid with food. </li>
<li>With exception of DRV/r and SQV/r, manufacturer recommends avoiding co-administration or use with caution with other PIs. </li>
</ul>
<a name="RENAL DOSING"></a>
<h2 class="grayLineHeaderBar">RENAL DOSING</h2>
<table  cellspacing="0" cellpadding="0" border="0">
<tr>
<td><span class="header12px">DOSING FOR GLOMERULAR FILTRATION OF 50-80</span></td>
</tr>
</table>
<hr>200 mg twice daily<br>
<br>
<table  cellspacing="0" cellpadding="0" border="0">
<tr>
<td><span class="header12px">DOSING FOR GLOMERULAR FILTRATION OF 10-50</span></td>
</tr>
</table>
<hr>No data. Usual dose likely since ETR and metabolites are not significantly excreted in urine. <br>
<br>
<table  cellspacing="0" cellpadding="0" border="0">
<tr>
<td><span class="header12px">DOSING FOR GLOMERULAR FILTRATION OF &lt;10 ML/MIN</span></td>
</tr>
</table>
<hr>No data. Usual dose likely since ETR and metabolites are not significantly excreted in urine. <br>
<br>
<table  cellspacing="0" cellpadding="0" border="0">
<tr>
<td><span class="header12px">DOSING IN HEMODIALYSIS</span></td>
</tr>
</table>
<hr>No data. Due to high protein binding, ETR is unlikely to be removed in dialysis. Usual dose likely.<br>
<br>
<table  cellspacing="0" cellpadding="0" border="0">
<tr>
<td><span class="header12px">DOSING IN PERITONEAL DIALYSIS</span></td>
</tr>
</table>
<hr>No data. Due to high protein binding, ETR is unlikely to be removed in dialysis. Usual dose likely.<br>
<br>
<table  cellspacing="0" cellpadding="0" border="0">
<tr>
<td><span class="header12px">DOSING IN HEMOFILTRATION</span></td>
</tr>
</table>
<hr>No data. Due to high protein binding, ETR is unlikely to be removed in dialysis. Usual dose likely.<br>
<br>
<a name="ADVERSE DRUG REACTIONS"></a>
<h2 class="grayLineHeaderBar">ADVERSE DRUG REACTIONS</h2>
<table  cellspacing="0" cellpadding="0" border="0">
<tr>
<td><span class="header12px">GENERAL</span></td>
</tr>
</table>
<hr>
<ul>
<li>ETR is generally well tolerated.</li>
</ul>
<table  cellspacing="0" cellpadding="0" border="0">
<tr>
<td><span class="header12px">COMMON</span></td>
</tr>
</table>
<hr>
<ul>
<li>In pts also treated with DRV/r, rash occurred in 17% in ETR treated group vs.9% in placebo-treated pts. </li>
<li>In general, rash was mild to moderate, occurred in 2nd wk and resolved within 1-2 wks on continued therapy. However, 2% required ETR discontinuation. Rash more commonly in women. </li>
<li>Pts with history of NNRTI-related rash did not have higher risk of rash with ETR. </li>
</ul>
<table  cellspacing="0" cellpadding="0" border="0">
<tr>
<td><span class="header12px">OCCASIONAL</span></td>
</tr>
</table>
<hr>
<ul>
<li>With DRV/r co-administration, moderate to severe (grade&nbsp;2-4) nausea, abdominal pain, <A class="headLines" target="_new" href="../../diagnosis/organ_system/diarrhea8e47.html?contentInstanceId=432753">diarrhea</A>, and vomiting reported in approximately 15% of pts comparable to placebo)</li>
<li>Grade of 2 or greater LFTs and bilirubin elevations more common in <A class="headLines" target="_new" href="../../diagnosis/opportunistic_infections/hepatitis_b4390.html?contentInstanceId=432701">HBV</A> and <A class="headLines" target="_new" href="../../diagnosis/opportunistic_infections/hepatitis_c7412.html?contentInstanceId=432702">HCV</A> co-infected pts.</li>
<li>AST, ALT, and bilirubin elevation occurred in 22.8%, 21.4%, and 5.7%, respectively, vs. 5.5%, 6.1%, and 1.2% of non-co-infected pts treated with ETR. </li>
<li>Fatigue (3.3%)</li>
<li>
<A class="headLines" target="_new" href="../../diagnosis/organ_system/neuropathy__peripheralce31.html?contentInstanceId=432761">Peripheral neuropathy</A> (2.8%)</li>
<li>Headache (2.7%)</li>
<li>Hypertension (2.8%) </li>
<li>Total cholesterol elevation (&gt;240 mg/dL) reported in 24% of ETR-treated pts vs. 17% of placebo-treated pnts. </li>
<li>Triglyceride elevation (&gt;500 mg/dL) in 14% of ETR-treated pts vs.11% of placebo-treated pts. </li>
<li>Hyperglycemia (&gt;161 mg/dL) in 16% of ETR-treated pts compared to 13% of placebo-treated pts. </li>
</ul>
<table  cellspacing="0" cellpadding="0" border="0">
<tr>
<td><span class="header12px">RARE</span></td>
</tr>
</table>
<hr>
<ul>
<li>Severe rash including Stevens-Johnson syndrome and erythema multiforme </li>
</ul>
<a name="DRUG INTERACTIONS"></a>
<h2 class="grayLineHeaderBar">DRUG INTERACTIONS</h2>
<ul>
<li>
<I>In vitro</I> ETR is CYP3A4, 2C19, and 2C9 substrate. Also undergoes glucuronidation. Not a Pgp substrate. Does not induce or inhibit its own metabolism. </li>
<li>ETR inhibits 2C9 and 2C19</li>
<li>Mild inducer of CYP3A4, 2B6, and glucuronidation <I>in vitro</I>. </li>
</ul>
<table  cellspacing="0" cellpadding="0" border="0">
<tr>
<td><span class="header12px">Drug-to-Drug Interactions</span></td>
</tr>
</table>
<hr>
<a name="Drug-to-Drug Interaction"></a>
<h2 class="grayLineHeaderBar">Drug-to-Drug Interaction</h2>
<TABLE class="blueOutline" CELLPADDING="2" CELLSPACING="0"  BORDER="0">
<tr class="blueBarBG">
<td>Drug</td><td>Effect of Interaction</td><td>Recommendations/Comments</td>
</tr>
<TR>
<TD valign="top"><B><A class="headLines" target="_new" href="../antimicrobial_agents/clarithromycin2448.html?contentInstanceId=434158">Clarithromycin</A>&nbsp;</B></TD><TD valign="top">ETR AUC increased by 42%. <A class="headLines" target="_new" href="../antimicrobial_agents/clarithromycin2448.html?contentInstanceId=434158">Clarithromycin</A> AUC decreased by 39%, but 14-OH-<A class="headLines" target="_new" href="../antimicrobial_agents/clarithromycin2448.html?contentInstanceId=434158">clarithromycin</A> increased by 21%. </TD><TD valign="top">Consider <A class="headLines" target="_new" href="../antimicrobial_agents/azithromycin9ba3.html?contentInstanceId=441410">azithromycin</A> for <A class="headLines" target="_new" href="../../diagnosis/opportunistic_infections/mycobacterium_avium_complex__mac___disseminatedc431.html?contentInstanceId=434821">MAC</A> treatment. Clinical significance unclear for infections involving <I>S. pneumoniae</I> and <I>H. influenzae</I> since 14-OH-<A class="headLines" target="_new" href="../antimicrobial_agents/clarithromycin2448.html?contentInstanceId=434158">clarithromycin</A> metabolite is active. </TD>
</TR>
<TR>
<TD valign="top"><B><A class="headLines" target="_new" href="../antimicrobial_agents/rifampicin532e.html?contentInstanceId=434653">Rifampin</A>&nbsp;</B></TD><TD valign="top">ETR's serum concentrations may be significantly decreased</TD><TD valign="top">Avoid co-administration</TD>
</TR>
<TR>
<TD valign="top"><B><A class="headLines" target="_new" href="maraviroc7e32.html?contentInstanceId=443126">Maraviroc</A>&nbsp;</B></TD><TD valign="top"><A class="headLines" target="_new" href="maraviroc7e32.html?contentInstanceId=443126">MVC</A> AUC decreased by 53%. ETR not affected </TD><TD valign="top">Increase <A class="headLines" target="_new" href="maraviroc7e32.html?contentInstanceId=443126">MVC</A> to 600 mg bid. If a CYP3A4 inhibitor, such as DRV/r, is co-administered with <A class="headLines" target="_new" href="maraviroc7e32.html?contentInstanceId=443126">MVC</A> plus ETR, decrease <A class="headLines" target="_new" href="maraviroc7e32.html?contentInstanceId=443126">MVC</A> to 150 mg bid. </TD>
</TR>
<TR>
<TD valign="top"><B>
            <A class="headLines" target="_new" href="atazanavir766b.html?contentInstanceId=441414">Atazanavir (ATV)</A>
          </B></TD><TD valign="top">With unboosted ATV co-administration ETR AUC increased by 50%, but ATV Cmin decreased by 47%. </TD><TD valign="top">Avoid unboosted ATV co-administration. </TD>
</TR>
<TR>
<TD valign="top"><B><A class="headLines" target="_new" href="fosamprenavir551f.html?contentInstanceId=441415">Fosamprenavir</A>/<A class="headLines" target="_new" href="ritonavir974c.html?contentInstanceId=432950">ritonavir</A> (FPV/r)</B></TD><TD valign="top">APV AUC12h, increased by 69%. ETR comparable to historical control. </TD><TD valign="top">Unclear clinical significance with FPV/r, but manufacturer recommends avoiding co-administration.</TD>
</TR>
<TR>
<TD valign="top"><B><A class="headLines" target="_new" href="saquinavir964d.html?contentInstanceId=432951">Saquinavir</A>/<A class="headLines" target="_new" href="lopinavir_ritonavir40d3.html?contentInstanceId=432947">lopinavir/ritonavir</A>(SQV/LPV/r)</B></TD><TD valign="top">Minor AUC changes in PIs </TD><TD valign="top">No dosage adjustments </TD>
</TR>
<TR>
<TD valign="top"><B><A class="headLines" target="_new" href="saquinavir964d.html?contentInstanceId=432951">Saquinavir</A>/ <A class="headLines" target="_new" href="ritonavir974c.html?contentInstanceId=432950">ritonavir</A> (SQV/r)</B></TD><TD valign="top">ETR AUC and Cmin decreased 33% and 29%, respectively. No significant change in SQV AUC.</TD><TD valign="top">No dosage adjustments necessary.</TD>
</TR>
<TR>
<TD valign="top"><B><A class="headLines" target="_new" href="tipranavir9ea2.html?contentInstanceId=443122">Tipranavir</A>/r (TPV/r)</B></TD><TD valign="top">ETR AUC decreased by 76%. TPV and RTV AUC increased by 18% and 23%, respectively.</TD><TD valign="top">Avoid co-administration </TD>
</TR>
<TR>
<TD valign="top"><B><A class="headLines" target="_new" href="darunavir4a48.html?contentInstanceId=443123">Darunavir</A>/ritonavir (DRV/r)</B></TD><TD valign="top">DRV AUC increased by 15%. ETR AUC and Cmin decreased by 37% and 49%, respectively. </TD><TD valign="top">Despite significant reduction in ETR serum concentrations, good virologic response observed in clinical trials. No dose adjustment necessary. </TD>
</TR>
<TR>
<TD valign="top"><B><A class="headLines" target="_new" href="didanosine10dd.html?contentInstanceId=432941">Didanosine</A> (ddl)</B></TD><TD valign="top">ETR AUC increased 11% (NS). No significant change in ddI AUC. </TD><TD valign="top">No dosage adjustments necessary.</TD>
</TR>
<TR>
<TD valign="top"><B><A class="headLines" target="_new" href="indinavirfd01.html?contentInstanceId=432945">Indinavir</A> (IDV)</B></TD><TD valign="top">IDV AUC decreased 46%, ETR AUC increased 51%</TD><TD valign="top">Unboosted PIs should be avoided with ETR. </TD>
</TR>
<TR>
<TD valign="top"><B><A class="headLines" target="_new" href="lopinavir_ritonavir40d3.html?contentInstanceId=432947">Lopinavir/ritonavir</A> (LPV/r)</B></TD><TD valign="top">LPV AUC decreased 20%(NS), ETR AUC increased 17% (NS) </TD><TD valign="top">No dosage adjustments necessary. Unclear clinical significance, but manufacturer recommends co-administration with caution</TD>
</TR>
<TR>
<TD valign="top"><B><A class="headLines" target="_new" href="ritonavir974c.html?contentInstanceId=432950">Ritonavir</A> (RTV 600 mg BID)</B></TD><TD valign="top">ETR AUC decreased 46%</TD><TD valign="top">Avoid co-administration with high dose RTV.</TD>
</TR>
<TR>
<TD valign="top"><B><A class="headLines" target="_new" href="tenofovir0121.html?contentInstanceId=439564">Tenofovir</A> (TDF)</B></TD><TD valign="top">ETR AUC decreased by 19%, TDF AUC increased by 15%</TD><TD valign="top">No dosage adjustments necessary.</TD>
</TR>
<TR>
<TD valign="top"><B>Antiarrhythmics: amiodarone, bepridil, disopyramide, flecainide, lidocaine, mexiletine, propafenone, and quinidine.</B></TD><TD valign="top">Antiarrhythmics serum concentrations may be decreased with ETR co-administration.</TD><TD valign="top">Use with caution. Monitor antiarrhythmics serum concentrations. </TD>
</TR>
<TR>
<TD valign="top"><B>Anticonvulsants: carbamazepine, phenobarbital, and phenytoin</B></TD><TD valign="top">ETR's serum concentrations may be significantly decreased</TD><TD valign="top">Avoid co-administration</TD>
</TR>
<TR>
<TD valign="top"><B>Antifungals</B></TD><TD valign="top">All azole antifungals may increase ETVRs serum concentrations. Itraconazole and ketoconazole's serum concentrations may be decreased with ETR co-administration. On the other hand, voriconazole's serum concentrations may be increased. <A class="headLines" target="_new" href="../antimicrobial_agents/fluconazoled462.html?contentInstanceId=434183">Fluconazole</A> and posaconazole are unlikely to be affected by ETR.</TD><TD valign="top">With ETR co-administration, monitor itraconazole and voriconazole serum concentrations. Dose adjustment may be needed.</TD>
</TR>
<TR>
<TD valign="top"><B>Atorvastatin&nbsp;</B></TD><TD valign="top">Atorvastatin AUC decreased by 37%. No change in ETR AUC</TD><TD valign="top">The dose of atorvastatin may need to be increased. </TD>
</TR>
<TR>
<TD valign="top"><B>ATV/r</B></TD><TD valign="top">With ATV/r co-administration ETR AUC increased by 30% and ATV AUC and Cmin decreased by 14% and 38%, respectively.</TD><TD valign="top">Unclear clinical significance, but manufacturer recommends avoiding co-administration.</TD>
</TR>
<TR>
<TD valign="top"><B>Dexamethasone</B></TD><TD valign="top">ETR serum concentrations may be decreased</TD><TD valign="top">Use with caution. Consider an alternative corticosteroid.</TD>
</TR>
<TR>
<TD valign="top"><B>Digoxin</B></TD><TD valign="top">Digoxin AUC increased by 18%</TD><TD valign="top">Limited data. Consider monitoring digoxin serum concentrations.</TD>
</TR>
<TR>
<TD valign="top"><B>Ethinylestradiol and Norethindrone</B></TD><TD valign="top">Ethinylestradiol AUC increased by 22%. Norethindrone AUC decreased by 5%. </TD><TD valign="top">Clinical significance unknown. Consider the use of an additional barrier form of contraception.</TD>
</TR>
<TR>
<TD valign="top"><B>HMG-CoA Reductase Inhibitors: lovastatin, simvastatin, fluvastatin, rosuvastatin and pravastatin</B></TD><TD valign="top">Lovastatin and simvastatin serum concentrations may be decreased. Fluvastatin serum concentrations may be increased. Rosuvastatin and pravastatin are unlikely to be affected with ETR co-administration.</TD><TD valign="top">Rosuvastatin and pravastatin may be considered. </TD>
</TR>
<TR>
<TD valign="top"><B>Immunosuppressants: cyclosporine, sirolimus, tacrolimus</B></TD><TD valign="top">ETR may decrease immunosuppressant serum concentrations.</TD><TD valign="top">Monitor serum concentrations of immunosuppressants closely with co-administration. </TD>
</TR>
<TR>
<TD valign="top"><B>Methadone&nbsp;</B></TD><TD valign="top">No change in active R(-) methadone</TD><TD valign="top">No dosage adjustments necessary</TD>
</TR>
<TR>
<TD valign="top"><B>Midazolam&nbsp;</B></TD><TD valign="top">Midazolam AUC decreased by 37%</TD><TD valign="top">Limited data. Titrate midazolam to effect. May also decrease triazolam serum concentrations. Lorazepam&nbsp;</TD>
</TR>
<TR>
<TD valign="top"><B>NFV</B></TD><TD valign="top">May decrease NFV serum concentrations</TD><TD valign="top">Unboosted PIs should be avoided with ETR.</TD>
</TR>
<TR>
<TD valign="top"><B>Omeprazole</B></TD><TD valign="top">ETR AUC increased 41% Omeprazole AUC increased 332% (limited data) </TD><TD valign="top">No dosage adjustments necessary.</TD>
</TR>
<TR>
<TD valign="top"><B>Raltegravir&nbsp;</B></TD><TD valign="top">ETR AUC increased by 10%. No significant change in RAL AUC. </TD><TD valign="top">No dosage adjustments necessary.</TD>
</TR>
<TR>
<TD valign="top"><B>Ranitidine</B></TD><TD valign="top">ETR AUC decreased 14%</TD><TD valign="top">No dosage adjustments necessary.</TD>
</TR>
<TR>
<TD valign="top"><B>Rifabutin&nbsp;</B></TD><TD valign="top">ETR AUC and Cmin decreased 37% and 35%, respectively. Rifabutin AUC decreased 17%. </TD><TD valign="top">Use standard dose rifabutin 300 mg daily, but avoid co-administration with DRV/r or SQV/r plus ETR due to potential additive decrease in ETR exposure. </TD>
</TR>
<TR>
<TD valign="top"><B>Rifapentine</B></TD><TD valign="top">ETR's serum concentrations may be significantly decreased</TD><TD valign="top">Avoid co-administration</TD>
</TR>
<TR>
<TD valign="top"><B>Sildenafil</B></TD><TD valign="top">Sildenafil AUC decreased 57%</TD><TD valign="top">Titrate sildenafil to effect</TD>
</TR>
<TR>
<TD valign="top"><B>St. John's Wort</B></TD><TD valign="top">ETR serum concentrations may be decreased</TD><TD valign="top">Avoid co-administration</TD>
</TR>
<TR>
<TD valign="top"><B>Warfarin</B></TD><TD valign="top">Warfarin AUC increased by 82%</TD><TD valign="top">Limited data. Use with close INR monitoring</TD>
</TR>
</TABLE>
<a name="RESISTANCE"></a>
<h2 class="grayLineHeaderBar">RESISTANCE</h2>
<ul>
<li>ETR maintained activity against multiple NNRTI resistance, including K103N and Y181C. </li>
<li>3 or more of following mutations at baseline associated with decreased response to ETR: V90I, A98G, L100I, K101E, K101P, V106I, V179D/F, Y181C/I, Y181V, G190A/s.</li>
<li>Highest level or resistance observed with following combination of mutations: V179F+Y181C (187 fold-change), V179F+Y181I (123 fold-change), or V179F +Y181C+F227C (888 fold-change). </li>
<li>Mutations that developed most commonly in subjects with virologic failure were V179F, V179I, Y181C, and Y181I. </li>
<li>Mutations associated with reduction in susceptibility of &gt;3-fold were K101A/P/Q, E138G/Q/C/I/T/V, and M230L. Of these, Y181I and Y181V resulted in the greatest reduction in susceptibility (13 and17-fold, respectively). </li>
</ul>
<a name="PHARMACOLOGY"></a>
<h2 class="grayLineHeaderBar">PHARMACOLOGY</h2>
<a name="N10AA1"></a>
<table  cellspacing="0" cellpadding="0" border="0">
<tr>
<td><span class="header12px">PHARMACOKINETIC PARAMETERS</span></td>
</tr>
</table>
<hr>
<ul>
<li>Absorption: 
                Absolute bioavailability unknown. </li>
<li>Metabolism and Excretion: 
                ETR undergoes oxidative metabolism by CYP3A4, CYP2C9, and CYP2C19 <I>in vitro</I>. ETR's methylhydroxylated metabolites have 90% less activity against wild-type virus compared to ETR. Primarily excreted in the feces with only 1.2% recovered in the urine. </li>
<li>Protein Binding: 
                99.9% </li>
<li>Cmax, Cmin, and AUC: 
                With DRV/r co-administration: ETR AUC12h (GM+/-SD): 4531 +/- 4543 ng h/m; ETR Cmin (GM+/-SD): 296 +/- 377 ng/mL </li>
<li>T1/2: 
                41 (+/- 20) hrs</li>
<li>Distribution: 
                Unknown distribution into CSF and genital tract secretion, but presumed to be low. </li>
</ul>
<table  cellspacing="0" cellpadding="0" border="0">
<tr>
<td><span class="header12px">DOSING FOR GLOMERULAR FILTRATION OF 50-80</span></td>
</tr>
</table>
<hr>
          
        
<br>
<br>
<table  cellspacing="0" cellpadding="0" border="0">
<tr>
<td><span class="header12px">DOSING FOR DECREASED HEPATIC FUNCTION</span></td>
</tr>
</table>
<hr>Child-Pugh Class A and B: 200 mg twice daily. Child-Pugh Class C: no data. Use with caution.<br>
<br>
<table  cellspacing="0" cellpadding="0" border="0">
<tr>
<td><span class="header12px">PREGNANCY RISK</span></td>
</tr>
</table>
<hr>Category B. No human data. Not teratogenic in animal studies. <br>
<br>
<table  cellspacing="0" cellpadding="0" border="0">
<tr>
<td><span class="header12px">BREAST FEEDING COMPATIBILITY</span></td>
</tr>
</table>
<hr>No data. Breast feeding is not recommended in the U.S. in order to avoid post-natal transmission of HIV to the child, who may not yet be infected.<a name="COMMENTS"></a>
<h2 class="grayLineHeaderBar">COMMENTS</h2>Pros: Active against most of the EFV- and <A class="headLines" target="_new" href="nevirapinebc24.html?contentInstanceId=432949">NVP</A>-resistant HIV strains, generally well tolerated, with higher genetic barrier to resistance compared to EFV and <A class="headLines" target="_new" href="nevirapinebc24.html?contentInstanceId=432949">NVP</A>. Cons: bid dosing, rash, and many complex drug interactions. <br>
<br>
<a name="N10AEF"></a><a name="References"></a>
<h2 class="grayLineHeaderBar">References</h2>
<ol>
<li>Richard Haubrich, P Cahn, B Grinsztejn, J Lalezari, J Madruga, A Mills, M Peeters, J Vingerhoets, K Iveson, G De Smedt, and on behalf of the DUET-1 study group.;
		
            <A class="headLines" target="_new" href="http://www.retroconference.org/2008/PDFs/791.pdf">DUET-1: Week-48 Results of a Phase III Randomized Double-blind Trial to Evaluate the Efficacy and Safety of TMC125 vs Placebo in 612 Treatment-experienced HIV-1-infected Patients.</A>
          ;        
		CROI 2008;
		February 3-6, 2008; Vol. 
		Abstract 790; pp. 
		<br>Rating:
			Important<br>
<b>Comments:</b>Treatment experienced pts with at least&nbsp;1 NNRTI mutation and at least 3 PI mutations randomized to placebo or ETR (+ DRV/r + OBR). Baseline characteristics (n=599) of pts on ETRBR were: VL= 4.8 log, CD4 99. 2/3 had extensive ARV treatment history (10-15 ARVs) , 69% had ./-2 detectable NNRTI mutations, 62% had &gt;/- 4 primary PI mutations, and only 4% had prior use of DRV/r. Virologic suppression (VL &lt;50) at 48 wks achieved in 61% of pts in the ETR arms compared with 40% in the placebo arms (p&lt;0.0001). Pooled DUET-1 and -2 data found mean -2.25 log reduction in the ETR arm vs. -1.49 log&nbsp;reduction in placebo arm (p&lt;0.0001). mean increase in CD4 from baseline was higher in the ETR arm (98 vs 73, p=0.0006). If ENF was used de novo, 71% of ETR-treated pts and 59% of placebo-treated pts achieved virologic suppression. ETR was generally well tolerated with rash occurring in 22% and 17% (DUET-1 and -2, respectively) in ETR group vs. only 11% in placebo group. However, rash led to discontinuation in only 2% of ETR-treated pts.<br>
<br>
</li>
<li>Margaret Johnson, T Campbell, B Clotet, C Katlama, A Lazzarin, W Towner, M Peeters, J Vingerhoets, S Bollen, G De Smedt, and on behalf of the DUET-2 study group.;
		
            <A class="headLines" target="_new" href="http://www.retroconference.org/2008/PDFs/790.pdf">DUET-2: Week-48 Results of a Phase III Randomized Double-blind Trial to Evaluate the Efficacy and Safety of TMC125 vs Placebo in 591 Treatment-experienced HIV-1-infected Patients.</A>
          ;        
		CROI 2008;
		February 3-6, 2008; Vol. 
		Abstract 791; pp. 
		<br>Rating:
			Important<br>
<b>Comments:</b>48-wk results of DUET-2<br>
<br>
</li>
</ol>
<br>
</td>
</tr>
</table>
</td><td></td>
</tr>
</table>
<p></p>
<table cellpadding="0" cellspacing="0" border="0" >
<tr>
<td bgcolor="#003366"></td><td class="bottomNav" bgcolor="#003366" >
<center>
<span class="copyrightFullModule">Copyright 2000-2008 Johns Hopkins University.  All rights reserved.</span>
</center>
</td>
</tr>
</table>
</body>

<!-- Mirrored from www.zambiahivguide.org/drugs/antiretrovirals/full_etravirine.html by HTTrack Website Copier/3.x [XR&CO'2007], Thu, 19 Jun 2008 21:24:50 GMT -->
</html>
